A report, achieving savings from high cost drugs published today sets out how commissioners and providers of NHS services can work together to achieve savings in the use of high cost drugs. These high cost drugs are excluded from the Payment by Results (PbR) tariff. The report is intended to support commissioners and providers in delivering their NHS Constitution obligations and in their introduction of the compliance regime for NICE Technology Appraisals.
Read achieving savings from high cost drugs.
A programme of work has been developed to implement the recommendations of Mark Hackett’s report homecare medicines – towards a vision for the future (December 2011). The majority of medicines supplied via homecare are excluded from the PbR tariff. This framework is pertinent to ensuring maximum efficiencies are realised from the Home Care Medicines Bill.
A letter from Mark Hackett highlights the potential savings, alongside improved governance arrangements for NHS organisations. It is important to consider all of these documents for the forthcoming (2013/14) planning round.